Literature DB >> 18609700

Autoantibodies in primary sclerosing cholangitis.

Johannes-Roksund Hov, Kirsten-Muri Boberg, Tom-H Karlsen.   

Abstract

The aetiology of primary sclerosing cholangitis (PSC) is not known and controversy exists as to whether PSC should be denominated an autoimmune disease. A large number of autoantibodies have been detected in PSC patients, but the specificity of these antibodies is generally low, and the frequencies vary largely between different studies. The presence of autoantibodies in PSC may be the result of a nonspecific dysregulation of the immune system, but the literature in PSC points to the possible presence of specific antibody targets in the biliary epithelium and in neutrophil granulocytes. The present review aims to give an overview of the studies of autoantibodies in PSC, with a particular emphasis on the prevalence, clinical relevance and possible pathogenetic importance of each individual marker.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609700      PMCID: PMC2721433          DOI: 10.3748/wjg.14.3781

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  144 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

2.  "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.

Authors:  B Terjung; U Spengler; T Sauerbruch; H J Worman
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients.

Authors:  S R Targan; C J Landers; L Cobb; R P MacDermott; A Vidrich
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

4.  Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC).

Authors:  J Sobajima; S Ozaki; H Uesugi; F Osakada; H Shirakawa; M Yoshida; K Nakao
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis.

Authors:  S Hardarson; D R Labrecque; F A Mitros; G A Neil; J A Goeken
Journal:  Am J Clin Pathol       Date:  1993-03       Impact factor: 2.493

6.  Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.

Authors:  H Locht; T Skogh; A Wiik
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

7.  Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.

Authors:  H Schultz; E Csernok; A Schuster; T S Schmitz; M Ernst; W L Gross
Journal:  Pediatr Allergy Immunol       Date:  2000-05       Impact factor: 6.377

8.  Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases.

Authors:  C Roozendaal; M A de Jong; A P van den Berg; R T van Wijk; P C Limburg; C G Kallenberg
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

9.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 10.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

View more
  36 in total

Review 1.  Clinical connection between rheumatoid arthritis and liver damage.

Authors:  Biljana Radovanović-Dinić; Snežana Tešić-Rajković; Valentina Zivkovic; Saša Grgov
Journal:  Rheumatol Int       Date:  2018-04-07       Impact factor: 2.631

Review 2.  Autoantibodies and liver disease: uses and abuses.

Authors:  Marilyn V Zeman; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2010-04       Impact factor: 3.522

Review 3.  [Primary sclerosing cholangitis : Current diagnostics and treatment].

Authors:  T Liwinski; C Schramm
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 4.  Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Claudia O Zein; Keith D Lindor
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 5.  Current management of primary sclerosing cholangitis in pediatric patients.

Authors:  Samar H Ibrahim; Keith D Lindor
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 6.  The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Kazuhito Kawata; Yoshimasa Kobayashi; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 7.  Genetics of primary sclerosing cholangitis and pathophysiological implications.

Authors:  Xiaojun Jiang; Tom H Karlsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

Review 8.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

Authors:  Bjarte Fosby; Tom H Karlsen; Espen Melum
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

Review 9.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

10.  Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.

Authors:  Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui
Journal:  J Immunol       Date:  2020-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.